Let the Old Model Die: Daiichi Sankyo Is Building an Oncology Empire

Daiichi Sankyo is no longer best understood as a successful Japanese pharma company with a strong oncology franchise. It is executing a deliberate corporate conversion into an oncology-centred platform company, built around proprietary ADC technology, globalised development and commercialisation capabilities, and a strong willingness to reshape its portfolio, operating model, and capital base around that thesis. The company’s recently released FY2026–FY2030 plan targets more than JPY 3.0 trillion in revenue by 2030, including more than JPY 2.3 trillion from oncology. Furthermore, Daiichi Sankyo is explicitly aiming for a top-five global oncology status by 2035. That ambition comes after FY2025 revenue reached JPY 2.123 trillion and oncology revenue reached JPY 954 billion, materially validating the earlier oncology pivot. 

Daiichi Sankyo’s transformation is real! The DXd platform is their engine. Enhertu and Datroway are the near-term value drivers. The strategic alliances with AstraZeneca and Merck have accelerated the company’s Western commercial reach while helping it absorb development risk. Official sources also support a subtler point embedded in the plan: this is not only about products, but the whole organisation is repurposed. Daiichi Sankyo has formalised a Technology Unit across biologics, pharmaceutical technology, and supply chain, launched a Smart Research Lab in San Diego, advanced Project 4D for data-driven management, and made “stand-alone” global clinical and commercial capability a stated strategic objective. 

The implications are straightforward. Daiichi Sankyo should be treated as a rising platform competitor in breast and lung cancer. They are now one of the most strategically important companies in ADCs. At the same time, it’s fair to point out that their model carries visible vulnerabilities:

• concentration in a few assets
• manufacturing complexity
• interstitial lung disease risk across the DXd class
• uneven Western reimbursement
• proof that even strong ADC franchises can fail at late-stage regulatory conversion, as their asset patritumab deruxtecan unfortunately showed. 

Strategic rationale

The most significant strategic fact is that Daiichi Sankyo has moved from “oncology expansion” to “oncology identity.” Its May 2026 plan does not present oncology as one growth pillar among many; it places oncology at the centre of revenue, capability-building, and longer-term corporate positioning. Management now frames the company’s success in terms of optimising five key oncology medicines, launching more than 20 new indications, and strengthening pricing and reimbursement capability. Simultaneously, they are building stand-alone development and commercial infrastructure to generate future profits. 

This strategic concentration is reinforced by portfolio pruning. In April, Daiichi Sankyo agreed to transfer all shares of Daiichi Sankyo Healthcare to Suntory Holdings in a staged transaction with expected consideration of JPY 246.5 billion in stages. As you understand, that is not a side note. It is evidence that management is willing to dispose of assets it now regards as non-core. It’s a strong path forward to sharpen focus and free capital for their oncology scale-up.

Daiichi Sankyo is adopting a slightly non-Japanese culture of learning from failure. Their Value Report 2025 explicitly describes a culture in which even failures are treated as valuable lessons and states that learnings from Exatecan and the discontinued DE-310 contributed to the creation of the proprietary DXd ADC platform. The same report describes “craftspersonship” as a long-standing operating principle and ties that mindset to the Technology Unit’s role in integrating development, manufacturing, and supply. 

A further strategic shift, and one that Western boards should not miss, is Daiichi Sankyo’s explicit desire to learn from alliances and eventually capture more value directly. The FY2025 results presentation states that the company intends to “build and strengthen robust stand-alone clinical development and commercial capabilities” by leveraging experience from its existing oncology alliances. This indicates that AstraZeneca and Merck are not merely distribution partners; they are also training grounds for Daiichi Sankyo’s own next phase.

Chart: Daiichi Sankyo evolution in oncology treatment.

The timeline clearly shows the empire-building logic: early platform validation, alliance-led scale, portfolio concentration, then a push toward stand-alone capability and second-wave pipeline renewal. That sequence is consistent across the company’s official plan, Value Report, and recent alliance announcements. 

Deal engine, pipeline strength, and the real risk balance

The DXd platform

The DXd platform remains the strategic moat. Official company materials and peer-reviewed literature consistently describe the core design features. It’s a topoisomerase I inhibitor payload, a cleavable tetrapeptide linker, a high drug-to-antibody ratio of about 8 for trastuzumab deruxtecan, and membrane permeability that has a bystander antitumor effect. Clinically, that design helped create the HER2-low treatment category and expand HER2-directed therapy beyond classical HER2-positive disease. 

Enhertu 

Enhertu remains the flagship asset and the economic proof point. In Daiichi Sankyo’s FY2025 materials, global alliance product sales reached JPY 698.4 billion, and management forecast JPY 861.3 billion for FY2026. The company also reported that Enhertu maintained the number-one new-patient share across major countries and regions. Regulatory momentum continues. FDA approved Enhertu plus pertuzumab for first-line HER2-positive metastatic breast cancer in late 2025, and the product also received US Priority Review in March 2026 for post-neoadjuvant HER2-positive early breast cancer, while EU approvals have expanded into HER2-low and HER2-ultralow disease after endocrine therapy. 

Datroway 

Datroway is the next major commercial pillar, but it is not yet a replica of Enhertu. FDA approved Datroway for previously treated HR-positive, HER2-negative metastatic breast cancer in January 2025, and later granted accelerated approval in June 2025 for adults with locally advanced or metastatic EGFR-mutated NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy. The EU approved Datroway for previously treated HR-positive, HER2-negative metastatic breast cancer in April 2025. This is meaningful breadth, but Western market access remains uneven. NICE suspended its appraisal for Datroway in this breast-cancer setting in February 2026 because the company did not provide an evidence submission. 

Patritumab deruxtecan 

Patritumab deruxtecan can be described as a cautionary asset. The product was positioned as an efficient way to extend the DXd franchise into EGFR-mutated NSCLC. HERTHENA-Lung02 reported a statistically significant progression-free survival benefit in 2024. But the US filing was first hit by a complete response letter tied to manufacturing concerns, and then the BLA was voluntarily withdrawn in May 2025. This is strategically important because it demonstrates that the Daiichi Sankyo platform does not neutralise classical late-stage oncology risk. 

Ifinatamab deruxtecan 

Ifinatamab deruxtecan is now the most visible next-wave swing asset. Daiichi Sankyo and Merck received US Priority Review in April 2026 for previously treated extensive-stage small cell lung cancer, and Merck reported a 48.2% objective response rate in phase 2. However, the program also illustrates class and execution risk: Fierce Biotech and BioSpace reported a partial clinical hold in late 2025/early 2026 tied to grade 5 ILD events in IDeate-Lung02, later lifted in the US according to BioSpace. Senior management should read this as a reminder that the same platform features driving efficacy also keep pulmonary toxicity and development friction squarely in view. 

Raludotatug deruxtecan 

Raludotatug deruxtecan and Daiichi Sankyo’s second-wave DXd ADC assets matter because they could reduce the company’s strategic dependence on Enhertu and Datroway. Raludotatug deruxtecan is being advanced in the phase 2/3 REJOICE-Ovarian01 program. The phase 2 dose-optimization portion selected 5.6 mg/kg for evaluation in the phase 3 portion. It received FDA Breakthrough Therapy Designation in September 2025 for CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers after prior bevacizumab. 

Beyond the current trio of partnered DXd programs, Daiichi Sankyo has started clinical work on DS3610 as a STING agonist ADC and DS3790 as the first haematology DXd ADC, signalling that management is already trying to ensure the company does not become a single-platform, two-asset story. 

The alliance architecture is as strategically important as the molecules. The AstraZeneca partnership gave Daiichi Sankyo immediate scale for Enhertu and Datroway. The Merck collaboration did something different: it monetised pipeline optionality at a large upfront value while preserving Daiichi Sankyo’s central manufacturing and, generally, global sales-booking role. Merck and Daiichi then extended that collaboration in 2024 to include gocatamig, a DLL3-targeting T-cell engager, with a $170 million upfront payment from Daiichi Sankyo to Merck and co-development economics outside Japan. This behaviour is atypical for the old Daiichi Sankyo that intended to remain a Japan-first licensor. 

Western commercial footprint and market access

Daiichi Sankyo’s Western exposure is already large in audited financial terms. In the fiscal year ended March 31, 2025, the company reported revenue of JPY 642.2 billion in the United States and JPY 418.2 billion in Europe, compared with JPY 583.8 billion in Japan and JPY 242.0 billion in ROW. On that audited basis, the US and Europe already accounted for roughly 56% of total revenue. That matters because it means the market outside of Japan is already the operating centre of gravity for the company’s revenue mix. My key takeaway is that Daiichi Sankyo is already moving strongly towards the 2035 results. The question that remains is: which one of today’s five largest pharmaceutical companies by oncology drug sales (Merck, AstraZeneca, J&J, BMS, Roche) will give up their place for Daiichi Sankyo?

Daiichi Sankyo’s Revenue per region.

The market-access machine is also becoming more sophisticated. In its FY2025 plan materials, Daiichi Sankyo said it had achieved more than 270 reimbursements across relevant products and indications, had reported more than 400 HEOR and real-world evidence studies, and had Enhertu approved in more than 95 countries or regions. Management’s explicit statement that long-term product value depends on pricing and reimbursement strategy is important because it signals a shift from “get the label” to “shape the Western treatment pathway.” 

That said, Western access remains uneven and diagnostic complexity is rising. NICE issued guidance for Enhertu for HER2-low metastatic or unresectable breast cancer in 2024, but the Datroway appraisal for breast cancer was suspended in February 2026 because the company did not submit evidence. In Canada, CADTH recommended reimbursement for trastuzumab deruxtecan in HER2-low metastatic breast cancer under specified conditions. These examples show that regulatory success is not equivalent to frictionless payer success, especially when the product is introduced earlier in treatment and budget impact increases. 

Western pathology and companion diagnostic practice have also become strategically important because Enhertu’s success depends in part on the clinical recognition of HER2-low and HER2-ultralow disease. FDA’s January 2025 approval in HR-positive HER2-low/HER2-ultralow metastatic breast cancer and international expert consensus recommendations on HER2 reporting both underline that Daiichi Sankyo’s commercial advantage is now tied not only to drug performance but also to the system’s ability to identify marginal-expression patients correctly. That is a durable commercial and market-access lesson for the entire sector. 

Regulatory, IP, financial, and valuation context

The regulatory picture is strong, but not clean. Enhertu continues to broaden its reach and is increasingly positioned for earlier use. Datroway has converted into a real market breadth. Ifinatamab has reached Priority Review. But patritumab’s withdrawal is the clearest reminder that the FDA will not allow platform prestige to substitute for confirmatory evidence or manufacturing robustness. The practical lesson is that Daiichi Sankyo’s empire is real, but it is still exposed to standard oncology failure modes. 

On intellectual property, one verified development is favourable to Daiichi Sankyo. In December 2025, the US Court of Appeals for the Federal Circuit vacated the infringement judgment and damages award in the Seagen dispute, and Daiichi Sankyo said the result nullified the previously imposed royalty and damages exposure tied to Seagen’s US Patent No. 10,808,039. For strategic planning, that removes an overhang on Enhertu economics. However, broader claims about exact future patent-expiry timing for the DXd platform were not independently verified from primary patent sources in the materials reviewed and should not be used for board-level planning without dedicated patent counsel review. 

Financially, the company’s long-term ambition remains impressive, but the near term reminds investors that ADC’s scale is operationally unforgiving. Daiichi Sankyo’s new plan includes more than JPY 200 billion of cost optimisation by 2030, yet the company also delayed FY2025 results and revised forecasts because it needed to reassess product-supply plans and loss provisions related to contract manufacturing. FirstWord reported that this disclosure contributed to a share-price drop of more than 10%, and later reporting described large compensation payments to CMOs and an impairment tied to the Odawara plant. This is not a contradiction in the strategy; it is the cost of trying to industrialise an oncology platform quickly. 

Valuation context, therefore, matters in a strategic, not merely trading, sense. Public market data services placed Daiichi Sankyo’s market capitalisation at roughly $30 billion in mid-May 2026. That is large enough to confirm that investors already view the company as a major oncology growth story; it is also modest enough to show that the market is still discounting concentration, manufacturing risk, and the question of how much of the next decade can be captured beyond Enhertu. 

Take aways

Western management teams should treat Daiichi Sankyo as a platform competitor first and an asset-level opportunity second. The company’s explicit move toward stand-alone global clinical development and commercial capabilities means that broad ex-Japan licensing is likely to become harder to secure and more expensive to structure. The more realistic partnership vectors are likely to be targeted combinations, diagnostics, digital pathology, biomarker discovery, evidence-generation support, and specialised manufacturing or supply-chain capability. Daiichi Sankyo’s recent collaborations with Tempus, 4D Path, and Waiv are consistent with that direction. 

Western oncology leaders should also assume that breast and lung cancer will remain Daiichi Sankyo’s primary invasion corridors. The company has said outright that it intends to maintain and expand leadership in breast cancer and to establish a strong leadership position in lung cancer. Since those are the most commercially strategic Western solid-tumour categories, incumbent companies should expect pressure on sequencing, earlier-line use, HEOR evidence generation, and disease-category framing, not just on product versus product competition. 

The most underappreciated lesson from Daiichi Sankyo’s building an oncology empire is that manufacturing and supply have become board-level strategic weapons in ADCs. The Technology Unit, the company’s “one-stop shop” ambition for ADC processing, and the recent forecast revision tied to supply-plan losses all point to the same conclusion: in this category, CMC excellence is no longer support work. It is a differentiator, a bottleneck, and a financial risk centre. Any Western company trying to compete in ADCs without comparable CMC strength is likely to be structurally disadvantaged. 

At the same time, the openings are real. Patritumab’s stumble proves that target adjacency and a strong platform are not enough. Ifinatamab’s safety history shows that class risk remains live. And market-access friction in the U.K. and other Western systems shows that clinical success still has to be converted into payer success. Western companies that can offer superior safety, cleaner clinical positioning, stronger companion-diagnostic execution, or better payer economics still have room to blunt Daiichi Sankyo’s momentum.